Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
Date:11/1/2010

ndidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.

Forward-Looking StatementsCertain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo-Kidney Augment and the Neo-Urinary Conduit; and (ii) expectations regarding ongoing and planned preclinical studies and clinical trials. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company will be able to obtain the capital it needs to develop its product candidates or continue as a going concern; (ii) the Company will be able to successfully enroll patients in its clinical trials, including its  Phase I clinical trial for the Neo-Urinary Conduit; (iii) patients enrolled in the Company's clinical trials will not experience adverse events related to the Company's product candidates, which could delay clinical trials or cause the Company to terminate the development of a product candidate; (iv) the results of the clinical trial for the Neo-Urinary Conduit will support further dev
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Medela announced today ... Biomedical Company (ABC), assigning Medela as the exclusive distributor ... known as the Medela Enteral Feeding Pump. Through this ... help NICU parents and healthcare professionals by offering a ... Medela Enteral Feeding Pump is integral to the delivery ...
(Date:9/23/2014)... Sept. 23, 2014 A case report and ... SynCardia temporary Total Artificial Heart into a patient with ... were reversed, along with other abnormalities. ... the SynCardia Total Artificial Heart to treat a patient ... and video in the Journal of Visualized Experiments show ...
(Date:9/23/2014)... September 23, 2014 BerGenBio ... company, today announces it has been granted a ... Award from the UK,s Wellcome Trust to develop ... novel cancer target. The Wellcome Trust ... fund especially promising, innovative new therapeutic concepts through ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
(Date:9/23/2014)... Becker's Hospital Review has published the ... and Health Systems With Great Orthopedic Programs." , ... list have orthopedic surgery departments, programs or dedicated ... sources. Exceptional orthopedic departments include physicians who provide ... treat professional athletes. , This is the fifth ...
(Date:9/23/2014)... under the curve of oxygen desaturation" (AUC Desat ) ... oxygen levels during procedures using sedation, according to a ... The AUC Desat provides information not only whether ... depth, duration, and rate of episodes of oxygen desaturation. ... University of Cincinnati and colleagues reports on the development ...
(Date:9/23/2014)... Ind. -- Contrary to what is often assumed about ... new study from The Kinsey Institute has found that ... are sexually active as often as singles without children ... children. , The study, "Dating and Sexual Behavior Among ... was published online in the Journal of Sex ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Kenall ... has expanded its MedMaster™ M4 product line with ... extends the M4 product line – currently available ... options – providing more flexibility when designing lighting ... MedMaster M4 Series include:, •Three sizes ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3
... Ill., Jan. 6 Baxter International,(NYSE: BAX ), ... 2008 financial results on Thursday, January 22, 2009, at 8:30 ... call, please dial,866-238-0637 (domestic) or 703-639-1156 (international). Please dial ... of the call for the operator to,connect you. , ...
... Jan. 6, 2009 AMERIGROUP Corporation (NYSE: AGP ... Annual J.P. Morgan Healthcare Conference on January 14 in San ... January 14 at 6:30 p.m. Eastern Time, can be accessed ... page. A replay will be available for 30 days, and ...
... of life improved , , TUESDAY, Jan. 6 (HealthDay News) -- ... stimulation improves both physical function and quality of life after ... stimulation (DBS) performed better than currently available drug treatments, but ... a study in the Jan. 7 issue of the ...
... Surf Sweets today announced,the introduction of its organic, natural ... country. Surf Sweets provides a natural, organic candy,option ... children. , Surf Sweets gummy ... ingredients without artificial flavors and colors. Surf Sweets ...
... 6 Karen Ignagni, President and CEO of America,s Health ... CMS today showing that health spending in the United States ... percent in 2007. According to the CMS report, private ... rate as in 2006, but much lower than the recent ...
... , ... Fla. (Vocus) January 6, 2009 -- Whether you commit to your new ... this year by bringing them in for regular check ups. Regular check ... to a loved one,s life saved and less costly medical bills for pet ...
Cached Medicine News:Health News:Deep Brain Stimulation Helps Those With Advanced Parkinson's 2Health News:Deep Brain Stimulation Helps Those With Advanced Parkinson's 3Health News:AHIP Statement on National Health Expenditure Data 2Health News:Early Detection Saves Pets 2Health News:Early Detection Saves Pets 3
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
... Featuring new technology, such as a recessed ... and lens housings, this arthroscope has superior ... by EO, Steris and steam autoclaving or ... Light post/adapters to fit ACMI, Wolf, Dyonics ...
... Passport II delivery device is the second ... C11UB. Its simple-to-use syringe technology allows one-handed ... small incision. The blue colored plunger allows ... protect the haptics during insertion. The modified ...
Medicine Products: